Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 206 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Marinol (dronabinol) Clear all
Completed Phase 1 Interventional Results available

Opioid and Cannabinoid Interactions

NCT03705559
View directory record Official record
Conditions
Marijuana Usage, Opioid Use
Interventions
Vaporized Marijuana, Opioid Agonist, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 6, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

Cannabidiol and Management of Endometriosis Pain

NCT04527003
View directory record Official record
Conditions
Endometriosis, CBD, Pelvic Pain
Interventions
Cannabidiol (CBD) Extract, Norethindrone Acetate, Placebo
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 6, 2026, 9:22 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

NCT06058702
View directory record Official record
Conditions
Schizophrenia, Cannabis Use Disorder
Interventions
Delta-9-THC Very Low Dose, Placebo, Delta-9-THC Medium Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

NCT05101122
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Dosing 1: Atomoxetine, AD313
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain

NCT02460692
View directory record Official record
Conditions
Cannabis, Low Back Pain, Neuropathic Pain
Interventions
Placebos, dronabinol, Vaporized Cannabis 3.7% THC/5.6% CBD
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
19 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 6, 2026, 9:22 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

NCT03206463
View directory record Official record
Conditions
Delta-9-Tetrahydroncannabinol, Bipolar Disorder, Healthy Controls
Interventions
4 mg Delta-9-THC, Placebo, 2 mg Delta-9-THC
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

NCT00642499
View directory record Official record
Conditions
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
36
States / cities
Bakersfield, California • Fresno, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol

NCT03164512
View directory record Official record
Conditions
Cannabidiol Pharmacokinetics
Interventions
Oral or vaporized cannabidiol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Individual Differences in Drug Response

NCT03809546
View directory record Official record
Conditions
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Interventions
Dronabinol, dextrose
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women

NCT03633721
View directory record Official record
Conditions
HIV, AIDS, Aging
Interventions
Cannabis, Placebo
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.

NCT00530764
View directory record Official record
Conditions
Palliative Care, Pain, Cancer
Interventions
Sativex Low Dose, Sativex Medium Dose, Sativex High Dose
Drug
Lead sponsor
GW Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Casa Grande, Arizona • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 6, 2026, 9:22 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

NCT02404688
View directory record Official record
Conditions
Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions
Active delta-9-THC, Placebo, Active Ethanol
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Age-Related Effects of THC

NCT04294966
View directory record Official record
Conditions
Tolerance, Adolescent Behavior, THC
Interventions
Dextrose, Dronabinol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 6, 2026, 9:22 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Research Investigating Drug Effects-2 (RiDE-2)

NCT06758596
View directory record Official record
Conditions
Cannabis Use, Substance Use Disorder (SUD), Healthy
Interventions
Placebo Oral Capsule, THC
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 21 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

NCT01361607
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Glendale, California • Santa Rosa, California • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 6, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Endocannabinoids in Reward

NCT07815691
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 45 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse

NCT00373503
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Lofexidine, dronabinol, Marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 6, 2026, 9:22 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

NCT06222268
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
Interventions
Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only, THC:CBD 1:1
Drug
Lead sponsor
Leslie Lundahl
Other
Eligibility
18 Years to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 6, 2026, 9:22 AM EDT
Not listed Phase 2 Interventional

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

NCT04091789
View directory record Official record
Conditions
Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions
Pure Femme Tablets
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Cannabinoid Response

NCT00678730
View directory record Official record
Conditions
COMT Gene Polymorphism
Interventions
delta 9 tetrahydrocannabinol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 6, 2026, 9:22 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

NCT06859710
View directory record Official record
Conditions
Abuse, Drug, Pain
Interventions
Placebo, THC, CBD 20 mg, CBD 40 mg, CBD 80 mg
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 6, 2026, 9:22 AM EDT
Completed Phase 2Phase 3 Interventional

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

NCT06146101
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
20
States / cities
Chula Vista, California • Long Beach, California • Upland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 6, 2026, 9:22 AM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 6, 2026, 9:22 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Synthetic THC And Blood Pressure

NCT07231965
View directory record Official record
Conditions
Blood Pressure
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 6, 2026, 9:22 AM EDT